More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wave of Debt Payments Facing US Government
- HP Comes in As Expected; Is It Time to Buy?
- Paul: Audit the Fed
- JAL Slides to Record Low on Bankruptcy Jitters
- Hewlett-Packard Profit Rises, Matches Guidance
- Prepare For Large Decline In Stocks, Next Year?
- The Social Media Gaming Threat
- Why Amazon Rules Retail
- Holiday Travel Outlook
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- Obama says Boosting US Jobs is Top Priority
- More Consumers Giving 'Black Friday' the Cold Shoulder
- Prepare For Large Decline In Stocks, Next Year?
- Hewlett-Packard Earnings Rise, Match Guidance
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com photo composite Gardasil |
] has been testing its cervical cancer vaccine Gardasil on young men (16-23 years old). The company says major data on those clinical trials are expected next year and could help Merck win FDA approval of the shots for males as well as females. The first-of-its-kind product has already sparked a sociopolitical controversy with its recommended use for young women. Imagine the brouhaha if or when Merck starts selling it for young men.That effort is getting a shot in the arm (bad, cliche pun intended) today from doctors at the prestigious M.D. Anderson Cancer Center who write a review in the medical journal "Cancer" about HPV-16 (one of the strains of the human papillomavirus that can lead to cancer) being tied to oropharyngeal, or a type of oral cancer.
The researchers conclude, "To hasten the reduction of HPV-16 in the population, widespread vaccination of adolescent and young adult males should also be considered. Although the cervical cancer...prevention policy of the HPV-16/18 (another leading cancer-causing strain) vaccination of young women and adolescent females are commended, we fear that vaccination programs limited to females will only delay the potential benefit in prevention of HPV-16/18-associated oropgaryngeal cancers, which typically occur in men. We encourage the rapid study of the efficacy and safety of these vaccines in males and, if successful, the recommendation of vaccination in young adult and adolescent males." One of the doctors who wrote the article has been a consultant for GSK.
Gardasil is well on its way to becoming a major blockbuster for Merck. GlaxoSmithKline [GSK
Loading...
()
] is awaiting FDA approval (for females) of a similar vaccine called Cervarix.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes